Last reviewed · How we verify
NCT07205536: ANC-IIT-004
A Clinical Study on the Safety and Efficacy of Mecapegfilgrastim in Preventing Myelosuppression Induced by Concurrent Chemoradiotherapy for Thoracic Malignancies
Phase 2 trial testing Mecapegfilgrastim injection in Myelosuppression in 30 participants. Currently enrolling.
1 December 2027
Quick facts
| Lead sponsor | Affiliated Hospital of Nantong University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 August 2025 |
| Primary completion | 1 December 2027 |
| Estimated completion | 1 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Mecapegfilgrastim injection — full drug profile →
- Oral or short-acting granulocyte-stimulating agents — full drug profile →
Conditions studied
- Myelosuppression — all drugs for Myelosuppression →
- Thoracic Neoplasms — all drugs for Thoracic Neoplasms →
- Chemoradiotherapy — all drugs for Chemoradiotherapy →
Sponsor
Affiliated Hospital of Nantong University
Who can join
Adults 18 to 75, any sex, with Myelosuppression or Thoracic Neoplasms. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Incidence of hematologic toxicity
Time frame: Day 7,Day 14
Hematologic toxicity, assessed by CBC performed 1 day before chemotherapy and on days 7 and 14 post-chemotherapy; CBC may be done at an external facility.
Sponsor's own description
This is a prospective observational study designed to observe and evaluate the safety and efficacy of mecapegfilgrastim in the treatment of moderate-to-severe myelosuppression associated with concurrent chemoradiotherapy. The project will provide more robust evidence-based medical support for the use of long-acting granulocyte-stimulating agents in patients undergoing concurrent chemoradiotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07205536
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myelosuppression
Currently open trials in the same condition.
- NCT06699472 — A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patie · Phase 2 · recruiting
- NCT06490081 — Trilaciclib Prevents Myelosuppression With Chemoradiotherapy · Phase 2 · recruiting
Other Affiliated Hospital of Nantong University trials
Trials by the same sponsor.
- NCT07506668 — RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas · Phase 1, PHASE2 · not yet recruiting
- NCT07342283 — QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer · Phase 2 · recruiting
- NCT07382453 — Effect of PAE Hydrogel Loaded With tRF-ASO-Exo on Patients With Diabetic Ocular Surface Diseases · Phase 2 · not yet recruiting
- NCT07247838 — Prospective Cohort Control Study on Changes in Gut Microbiota in Ischemic Stroke · recruiting
- NCT07271147 — Effects of taVNS Combined With Dexmedetomidine on POVN · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07205536 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital of Nantong University
- Last refreshed: 10 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07205536.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing